Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Instituto de Investigación Biomédica de Salamanca
Salamanca, EspañaPublications in collaboration with researchers from Instituto de Investigación Biomédica de Salamanca (46)
2024
2023
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Cells, Vol. 12, Núm. 15
-
Uncertainty to Improve the Automatic Measurement of Left Ventricular Ejection Fraction in 2D Echocardiography Using CNN-Based Segmentation
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
-
Myosin Vb as a tumor suppressor gene in intestinal cancer
Oncogene, Vol. 41, Núm. 49, pp. 5279-5288
2021
-
A platform to support the visual analysis of the SALMANTICOR study outcomes: Conveying cardiological data to lay users
ACM International Conference Proceeding Series
-
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
Modern Pathology, Vol. 34, Núm. 1, pp. 59-69
-
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Cancers, Vol. 13, Núm. 7
-
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
Cell Death and Disease, Vol. 12, Núm. 4
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation
Cancers, Vol. 12, Núm. 8, pp. 1-22
-
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Leukemia, Vol. 34, Núm. 8, pp. 2000-2011
2019
-
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Blood
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers
Journal of Immunological Methods, Vol. 475
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
-
YRNAs overexpression and potential implications in allergy
World Allergy Organization Journal, Vol. 12, Núm. 8